Gilles A. Salles, MD, PhD, on Follicular Lymphoma: Long-Term Results From the PRIMA Trial
2017 ASH Annual MeetingGilles A. Salles, MD, PhD, of the Université de Lyon, discusses study findings on rituximab maintenance after induction immunochemotherapy and the significant long-term progression-free survival benefit over observation (Abstract 486).
Related Videos
Mark J. Roschewski, MD, on Burkitt Lymphoma: Clinical Trial Results on DA-EPOCH-R
Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of ...
John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study
John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapse...
Joseph M. Connors, MD, on Untreated Hodgkin Lymphoma: Results From the ECHELON-1 Trial
Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazin...
Carla Casulo, MD, on Follicular Lymphoma: Results From the FLASH Study
Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from mor...
Jia Ruan, MD, on Mantle Cell Lymphoma: Study Results on Lenalidomide and Rituximab
Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a hig...
